{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-092661","form_type":"8-K","ticker":"APM","cik":"0001734005","company_name":"Aptorum Group Ltd","filed_at":"2026-08-21T21:00:33+00:00","discovered_at":"2026-08-21T21:02:08.545799+00:00","generated_at":"2026-08-21T21:02:28.673058+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Niki BioSolutions posts H1 2026 net loss of $1.3M, flags going-concern doubt","bullets":["H1 2026 net loss attributable to Niki was $1,326,004 vs $441,780 in H1 2025; EPS loss of $1.6.","Cash fell to $1,834,171 from $3,452,891 at Dec 31, 2025; operating cash outflow of $1,553,720.","Management disclosed substantial doubt about going concern within next 12 months; negative working capital of $2,475,418.","R&D expenses rose to $383,752 from $19,375 in H1 2025; related-party convertible notes total $3,508,500.","1-for-10 reverse stock split effective July 20, 2026; 1,979,216 shares issued to DiamiR stockholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-092661","json":"https://secwatch.observer/filing/0001213900-26-092661.json","markdown":"https://secwatch.observer/filing/0001213900-26-092661.md","text":"https://secwatch.observer/filing/0001213900-26-092661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1734005/000121390026092661/0001213900-26-092661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1734005/000121390026092661/ea0302544-8k_nikibio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-21T21:02:28.673058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}